In FTO-overexpressing HASMCs, we showed that CAD susceptibility genes were differentially methylated and that some of the m6A-SNPs were located in a differentially methylated peak (e.g., rs216196 in SMG6). This evidence concerns the gene FTO and coronary artery disorder.